These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 16408158)

  • 1. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.
    Iannello A; Ahmad A
    Cancer Metastasis Rev; 2005 Dec; 24(4):487-99. PubMed ID: 16408158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
    Green SK; Karlsson MC; Ravetch JV; Kerbel RS
    Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
    Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
    Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
    Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
    Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human anti-murine immunoglobulin responses and immune functions in cancer patients receiving murine monoclonal antibody therapy.
    Blottière HM; Steplewski Z; Herlyn D; Douillard JY
    Hum Antibodies Hybridomas; 1991 Jan; 2(1):16-25. PubMed ID: 1908336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
    Strome SE; Sausville EA; Mann D
    Oncologist; 2007 Sep; 12(9):1084-95. PubMed ID: 17914078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody.
    Nakamura K; Hanibuchi M; Yano S; Tanaka Y; Fujino I; Inoue M; Takezawa T; Shitara K; Sone S; Hanai N
    Cancer Res; 1999 Oct; 59(20):5323-30. PubMed ID: 10537316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective.
    Desjarlais JR; Lazar GA; Zhukovsky EA; Chu SY
    Drug Discov Today; 2007 Nov; 12(21-22):898-910. PubMed ID: 17993407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies: the possibilities for cancer therapy.
    Poynton CH; Reading CL
    Exp Biol; 1984; 43(1):13-33. PubMed ID: 6398221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different types of FCgamma-receptors are involved in anti-Lewis Y antibody induced effector functions in vitro.
    Dettke M; Loibner H
    Br J Cancer; 2000 Jan; 82(2):441-5. PubMed ID: 10646902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
    Imai M; Ohta R; Varela JC; Song H; Tomlinson S
    Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotherapy of ovarian cancer.
    Lidor Y; Bast RC
    Nat Immun Cell Growth Regul; 1988; 7(4):193-215. PubMed ID: 3070370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies: therapeutic possibilities and limitations].
    Tax WJ; Capel PJ; Koene RA
    Tijdschr Kindergeneeskd; 1987 Feb; 55(1):1-9. PubMed ID: 3551184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible applications of antibodies or their genes in cancer therapy.
    Kuroki M; Huang J; Shibaguchi H; Tanaka T; Zhao J; Luo N; Hachimine K; Kinugasa T; Maekawa S; Enatsu S; Hamanaka W; Fukami T; Kuroki M
    Anticancer Res; 2006; 26(6A):4019-25. PubMed ID: 17195452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S; Misaka H; Inoue M; Shibata M; Nakano R; Yamane-Ohnuki N; Wakitani M; Yano K; Shitara K; Satoh M
    Clin Cancer Res; 2006 May; 12(9):2879-87. PubMed ID: 16675584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies.
    Nechansky A; Schuster M; Jost W; Siegl P; Wiederkum S; Gorr G; Kircheis R
    Mol Immunol; 2007 Mar; 44(7):1815-7. PubMed ID: 17011625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
    Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
    Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.